Cravedi, P.; Brusegan, V.; Ruggenenti, P.; Campbell, R.; Remuzzi, G.
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals 2010, 3, 1-9.
https://doi.org/10.3390/ph3010001
AMA Style
Cravedi P, Brusegan V, Ruggenenti P, Campbell R, Remuzzi G.
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals. 2010; 3(1):1-9.
https://doi.org/10.3390/ph3010001
Chicago/Turabian Style
Cravedi, Paolo, Varusca Brusegan, Piero Ruggenenti, Ruth Campbell, and Giuseppe Remuzzi.
2010. "Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?" Pharmaceuticals 3, no. 1: 1-9.
https://doi.org/10.3390/ph3010001
APA Style
Cravedi, P., Brusegan, V., Ruggenenti, P., Campbell, R., & Remuzzi, G.
(2010). Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals, 3(1), 1-9.
https://doi.org/10.3390/ph3010001